CFR vs FRHC

CFR presents a dichotomy between exceptional earnings consistency and deteriorating financial health, as evidenced by a weak Piotroski F-Score of 3/9. While the stock trades between its Graham Number ($123.50) and Intrinsic Value ($191.38), the high PEG ratio of 2.38 and a bearish technical trend (10/100) suggest limited immediate upside. Strong ROE (15.31%) and a sustainable dividend payout (39.82%) provide a fundamental floor, but insider selling and poor deterministic health scores warrant a cautious approach. The company remains a stable earner, but current valuation and health metrics indicate a period of stagnation.

FRHC exhibits a severe disconnect between its market price and fundamental value, highlighted by a Piotroski F-Score of 4/9 (Stable/Weak) and a Graham Number of $3.2 against a current price of $151.15. The company is currently trading at an astronomical P/E ratio of 7557.50, while reporting negative YoY revenue growth (-14.10%) and dismal profitability metrics (ROE of 0.22%). Despite a positive 5-year price trajectory, recent quarterly earnings have consistently missed estimates with an average surprise of -129.39%, suggesting a bubble-like valuation unsupported by current cash flow or earnings power.